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Summary
 
4-1BB ligand (4-1BBL) is a member of the tumor necrosis factor (TNF) family expressed on
activated antigen-presenting cells. Its receptor, 4-1BB, is a member of the TNF receptor family
expressed on activated CD4 and CD8 T cells. We have produced a soluble form of 4-1BBL us-
ing the baculovirus expression system. When coimmobilized on plastic with anti-CD3, soluble
4-1BBL induces interleukin (IL)-2 production by resting CD28
 
1
 
 or CD28
 
2
 
 T cells, indicating
that 4-1BBL can function independently of other cell surface molecules, including CD28, in
costimulation of resting T cell activation. At low concentrations of anti-CD3, 4-1BBL is infe-
rior to anti-CD28 in T cell activation. However, when 4-1BB ligand is provided together with
strong TCR signals, then 4-1BBL and anti-CD28 are equally potent in stimulation of IL-2
production by resting T cells. We find that TNF receptor–associated factor (TRAF)1 or
TRAF2 associate with a glutathione S-transferase–4-1BB cytoplasmic domain fusion protein in
vitro
 
. 
 
In T cells, we find that association of TRAF1 and TRAF2 with 4-1BB requires 4-1BB
cross-linking. In support of a functional role for TRAF2 in 4-1BB signaling, we find that resting T
cells isolated from TRAF2-deficient mice or from mice expressing a dominant negative form
of TRAF2 fail to augment IL-2 production in response to soluble 4-1BBL. Thus 4-1BB, via
the TRAF2 molecule, can provide CD28-independent costimulatory signals to resting T cells.
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T
 
cells require two signals for activation, an antigen-spe-
cific MHC-restricted signal through the TCR and a
second costimulatory signal. CD28 on T cells is widely con-
sidered as the primary receptor for delivering costimulatory
signals to resting T cells (1). However, CD28
 
2
 
 T cells are
not defective in all responses, suggesting the existence of other
costimulatory pathways (2–4). One such alternate costimu-
latory pathway involves the TNFR family member 4-1BB
(CDw137), a T cell activation antigen found on activated
CD4 and CD8 T cells (5, 6). The ligand for 4-1BB is
found on activated B cells, macrophages, and cultured den-
dritic cells, as well as on several B lymphomas and the thy-
moma, EL4 (7–11).
A number of studies have shown a role for 4-1BB in T
cell activation using either transfected ligand (7), antibodies
against the 4-1BB molecule (6, 12–14), or blocking studies
with a soluble form of the 4-1BB receptor (10, 11, 15, 16).
Anti–4-1BB antibodies are effective in the activation of T
cells that have been preactivated via their TCR to induce
high levels of 4-1BB receptor expression (12), but are
poorer agonists for induction of IL-2 by resting T cells (6).
More recently, Shuford et al. have shown that anti–4-1BB
antibodies induce higher levels of proliferation of CD8 T
cells compared with CD4 T cells, leading to the suggestion
that 4-1BB is primarily a costimulatory molecule for CD8
T cells (14). In contrast, studies with APCs that express
4-1BB ligand (4-1BBL)
 
1
 
 have shown that 4-1BB interac-
tion with its ligand can participate in induction of prolifer-
ation and IL-2 and IL-4 production by CD4 T cells. This
role for 4-1BBL in the development of Th1 and Th2 cells
is most apparent in the absence of a strong B7-CD28 inter-
action (11, 16).
 
1
 
Abbreviations used in this paper:
 
 4-1BBL, 4-1BB ligand; AP, alkaline phos-
phatase; CT, cytoplasmic tail; DN, dominant negative; GST, glutathione
S-transferase; HA, hemagglutinin; ICAM-1, intercellular adhesion mole-
cule 1; JNK, c-Jun NH
 
2
 
-terminal kinase; NF-
 
k
 
B, nuclear factor–
 
k
 
B; RT,
reverse transcriptase; s4-1BBL, soluble form of 4-1BBL; TRAF, TNF re-
ceptor–associated factor.
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Despite the accumulating body of evidence on the im-
portance of 4-1BB as a costimulatory receptor on activated
CD4 and CD8 T cells, there is controversy as to whether
4-1BBL alone can provide a costimulatory signal for resting
T cells independently of other molecules present on the
APC. In this report we describe the production of a soluble
form of 4-1BBL (s4-1BBL) using the baculovirus expres-
sion system. When coimmobilized on plastic with anti-
CD3 or when cross-linked in solution through its influenza
hemagglutinin (HA) epitope tag, we find that s4-1BBL is a
potent activator of IL-2 production by isolated high density
CD28
 
1
 
 or CD28
 
2
 
 T cells. When TCR signals are limiting,
we find that immobilized anti-CD28 is more effective than
4-1BBL in inducing IL-2 production. However, at higher
anti-CD3 concentrations, 4-1BBL and anti-CD28 are equally
potent in inducing IL-2 production by resting T cells.
Thus, isolated 4-1BBL can costimulate resting T cells via a
CD28-independent pathway.
The observation that 4-1BB signaling can replace CD28
signaling in costimulation of T cell activation under some
circumstances raises the question of how signals from the
4-1BB receptor synergize with signals from the TCR to
induce high level IL-2 production. 4-1BB is a member of
the TNFR superfamily. Other members of this family have
been shown to signal via the TNFR-associated factor
(TRAF) family of signaling molecules first identified by
their ability to interact with the cytoplasmic domains of
TNFR family members (17, 18). Six members of the
TRAF family (TRAF1–6) have been identified to date
(17–25). The TRAF proteins appear to function as adapter
proteins that link TNFR family members to downstream
signaling pathways. TRAF family members have in com-
mon a conserved TRAF-C domain involved in homotypic
interactions or in heterotypic interactions with other TRAF
molecules and with the cytoplasmic tails of TNFR family
members. The TRAF2 molecule has been shown to inter-
act directly with the cytoplasmic tails of CD40, CD30, and
TNFR2 and indirectly with TNFR1 (17, 18, 26–31) and has
been shown to induce both nuclear factor (NF)-
 
k
 
B and c-Jun
NH
 
2
 
-terminal kinase (JNK) activation in response to TNF
stimulation (26, 32–34).
Transgenic mice expressing a dominant negative (DN)
form of TRAF2 (TRAF2 241-501) in their lymphoid cells
(TRAF2 DN mice) have reduced JNK activity, but rela-
tively normal NF-
 
k
 
B activation (35). Similar results have
also been obtained using mice that have been rendered
TRAF2 negative by gene targeting (36). Here we show
that T lymphocytes isolated from traf2
 
2
 
/
 
2
 
 or TRAF2 DN
mice fail to augment IL-2 production in response to s4-
1BBL. Thus the 4-1BB costimulatory signal leading to IL-2
production is dependent on the TRAF2 molecule.
 
Materials and Methods
 
Cell Lines, Mice, Antibodies and Reagents.
 
The T hybrid, C8.A3,
was obtained from Dr. Laurie Glimcher (Harvard Medical
School, Boston, MA). CD28
 
2
 
 mice (2) were backcrossed on to
the H-2
 
b
 
 background (
 
n
 
 5 
 
10). C57BL/6 mice were obtained
from Charles River Laboratories (St. Constant, Quebec, Canada).
CD28
 
2
 
 or B6 mice were used at 8–10 wk of age.
TRAF2 DN mice have been described previously (35). These
mice had been backcrossed on to the BALB/c background.
TRAF2 DN mice express TRAF2 (241-501) under the control
of the IgH enhancer to drive the transgene expression only in B
and T cells. TRAF2 (241-501) lacks the RING finger domain
and this form of TRAF2 has been previously shown to act as a
dominant negative inhibitor of TNF and CD40 signaling (26).
Spleen cells and lymph nodes were obtained from TRAF2 DN
mice or their transgene-negative littermates at 8–10 wk of age.
traf2
 
2
 
/
 
2
 
 mice were generated by gene targeting as described
elsewhere (36). TRAF2 expression was ablated using a replace-
ment vector that replaces the entire RING finger coding region
and intervening intron of traf2 with the PGK-Neo gene in the
reverse orientation to the endogenous 
 
traf2
 
 gene. traf2
 
2
 
/
 
2
 
 mice
were generated by breeding heterozygous mice. Lymph nodes
were obtained from surviving traf2
 
2
 
/
 
2
 
 mice or their traf2
 
1
 
/
 
1
 
 lit-
termates at 
 
z
 
3 wk of age. Hereafter, we will refer to these mice
as TRAF2
 
2
 
 and TRAF2
 
1
 
, respectively.
Mice overexpressing TRAF1 under control of the H-2
 
k
 
 pro-
moter have been described previously (38). These mice express
 
z
 
10-fold more TRAF1 in their spleen and lymph nodes com-
pared with wild-type mice, but have normal numbers of lympho-
cytes in their peripheral lymphoid organs. The anti-CD3-pro-
ducing hybridoma 145-2C11 (39) was provided by Dr. Jeff
Bluestone (University of Chicago, Chicago, IL). The 12CA5
producing hybridoma (40) was obtained from Dr. Bob Phillips
(University of Toronto, Toronto, Canada). The hybridomas
N418 (anti-CD11c), Y3-P (anti-A
 
b
 
), RA3-6B2 (anti-B220),
TIB-128 (anti-MAC-1), YN1/1.7.4 (anti–intercellular adhesion
molecule [ICAM]-1), RG7/7.6H2 (anti–rat Ig 
 
k
 
 chain), and
M1/69 (anti–heat stable antigen) were obtained from the Ameri-
can Type Culture Collection (Rockville, MD). Antibodies were
purified from hybridoma supernatants using protein G– or pro-
tein A–Sepharose (Pharmacia Biotech, Piscataway, NJ), according
to the manufacturer’s instructions. The anti–CD28-secreting hy-
bridoma 37.51.1 (41) was provided by Dr. Jim Allison (University
of California, Berkeley, CA). 3T3 cells secreting 4-1BB linked to al-
kaline phosphatase (AP) were provided by Dr. Byoung Kwon
(Indiana University, Indianapolis, IN). 4-1BB–AP was purified
on anti–AP-Sepharose as previously described (9). AP from human
placenta was obtained from Sigma Chemical Co. (St. Louis, MO).
Anti–4-1BB (1AH2) was purchased from Pharmacia Biotech.
 
Generation of s4-1BBL.
 
4-1BBL is a type II glycoprotein. To
generate s4-1BBL in insect cells, we linked cDNA encoding the
4-1BBL extracellular COOH-terminal domain to the signal se-
quence from myelin-associated glycoprotein, a signal sequence
previously shown to be effective in directing the secretion of het-
erologous proteins in the baculovirus expression system (refer-
ence 42 and see Fig. 1 
 
A
 
). An HA epitope tag was linked to the
COOH terminus of the 4-1BBL molecule to facilitate isolation of
the secreted molecule.
cDNA encoding the extracellular domain of 4-1BBL was ob-
tained by reverse transcriptase (RT) PCR amplification of RNA
isolated from the BALB/c B lymphoma K46J, since this cell line
has been shown to express functional 4-1BBL. RNA was ex-
tracted from K46J cells using Promega RNAgents Total RNA
Isolation System (Promega Corp., Madison, WI). Single-stranded
cDNA was synthesized from 2 
 
m
 
g of total RNA using the First-
Strand cDNA Synthesis Kit (Pharmacia Biotech). PCR was per-
formed with the primers 5
 
9
 
-GCT TCT CGA GGG GGA CAC 
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CGC ACC GAG CCT CGG CCA GC-3
 
9
 
 and 5
 
9
 
-ATT GCC
GGC CCT TCC CAT GGG TTG TCG GGT T-3
 
9
 
 (Oligonu-
cleotide Synthesis Laboratory, University of Toronto, Toronto,
Canada) and 1 
 
m
 
g of template cDNA, using an initial 2-min de-
naturation at 94
 
8
 
C, followed by 30 cycles of each of the follow-
ing: 94
 
8
 
C for 1 min, 55
 
8
 
C for 1 min, and 72
 
°
 
C for 1 min, and a
final 6-min extension at 72
 
8
 
C to produce a 645-bp product (in-
cluding 4-1BBL 104-309). The PCR product was inserted into
the pCR II vector using the TA Cloning Kit (Invitrogen Corp.,
Carlsbad, CA) and transformed into One Shot Cells (Invitrogen
Corp.) for sequencing using the T7 Sequencing Kit (Pharmacia
Biotech). Four independently derived RT-PCR products, de-
rived from the K46J cell line, were sequenced. Sequencing of
these independently derived RT-PCR products revealed a differ-
ence from the published sequence of C to A at NTD 476, result-
ing in a change from Lys to Gln at amino acid 142. Goodwin et al.
originally isolated 4-1BBL from the EL4 thymoma, which origi-
nates from C57Bl/6 mice, whereas the 4-1BBL cDNA isolated
here was from a BALB/c lymphoma (7). Therefore, this differ-
ence in sequence may represent a polymorphism between mouse
strains.
The myelin-associated glycoprotein (MAG) signal sequence
was added 5
 
9
 
 to the 4-1BBL 104-309 gene by subcloning into the
XhoI–AvaI sites of pShoNEX 1.1 (obtained from Rob Dunn,
McGill University, Montreal, Canada). The HA tag was added 3
 
9
 
to the MAG–4-1BBL 104-309 gene by NheI insertion into the
baculovirus vector pETL-HA (obtained from C. Richardson,
Amgen Institute, Toronto, Canada; reference 43). The recombi-
nant gene was inserted by homologous recombination into the
wild-type AcMNPV baculovirus in SF9 cells by cotransfection
using the Linear Transfection Module (Invitrogen Corp.). Re-
combinant baculovirus clones were identified by plaque assay,
and their purity was confirmed by PCR analysis using the primers
5
 
9
 
-TTT ACT GTT TTC GTA ACA GTT TTG-3
 
9
 
 and 5
 
9
 
-
CAA CAA CGC ACA GAA TCT AG-3
 
9
 
.
s4-1BBL in SF9 cell supernatants was detected by capture
ELISA using antibodies to the HA tag (12CA5) for capture and
s4-1BB receptor, 4-1BB–AP, for detection. Wells were coated at
37
 
8
 
C for 1 h with 20 
 
m
 
g/ml (100 
 
m
 
l/well) of 12CA5 in PBS.
Wells were then blocked with PBS/5% skim milk/0.1% Tween
20 two times for 30 min at 37
 
8
 
C. After blocking, the wells were
coated with various dilutions of supernatants from uninfected cul-
tures or cultures infected with recombinant or wild-type virus
(100 
 
m
 
l). After 90 min at room temperature, wells were washed
three times with PBS/0.1% Tween 20. 5 
 
m
 
g/ml of 4-1BB–AP
(100 
 
m
 
l/well) diluted in PBS/5% skim milk/0.1% Tween 20 was
added to each well for 45 min at room temperature, and plates were
washed three times with PBS/0.1% Tween 20. Finally, 1 mg/ml
of 
 
p
 
-nitrophenylphosphate (Sigma Chemical Co.) in 10% dietha-
nolamine was added to the wells, and OD
 
405
 
 was measured using
a Titertek Plus reader (Flow Laboratories, McLean, VA).
The recombinant virus was amplified in SF9 cells grown in
Grace’s insect media supplemented with 2% lactalbumin hydroly-
sate (GIBCO BRL, Gaithersburg, MD), 2% yeastolate (GIBCO
BRL), plus 10% fetal bovine serum (GIBCO BRL), and titered
by plaque assay before use for protein production.
 
Purification of s4-1BBL.
 
s4-1BBL was produced and purified
as follows. A 3-liter suspension culture of 1–2 
 
3 
 
10
 
6
 
 SF9 cells/ml
grown in SF900II (GIBCO BRL) at room temperature was in-
fected with recombinant virus at a multiplicity of infection of 10–
20 and harvested 6 d after infection. s4-1BBL molecules were pu-
rified from the supernatant by affinity chromatography on 12CA5
Sepharose. 12CA5 Sepharose 4B was prepared using cyanogen
bromide–activated Sepharose (Pharmacia Biotech) according to
the manufacturer’s instructions. To ensure that effects of s4-1BBL
were not influenced by the presence of endotoxin, the level of
endotoxin in the purified s4-1BBL was measured using the Lim-
ulus amebocytes lysate QCL 1000 kit (BioWhittaker Inc., Walk-
ersville, MD) and found to be less than 0.1 U/ml.
 
Generation of 4-1BB Cytoplasmic Tail (CT)–GST Fusion and
Measurement of 4-1BB CT–TRAF Association.
 
The entire cytoplas-
mic tail of 4-1BB was obtained by PCR from the 4-1BB full length
cDNA using primers 5
 
9
 
-GGGAATTCAAATGGATCAGG-
AAAAAATTCCC-3
 
9
 
 and 5
 
9
 
-GGGGATCCTCACAGCTCAT-
AGCCTCCTCCTC-3
 
9
 
. Amplified PCR fragments were se-
quenced and fused in-frame to GST by cloning into EcoRI and
BamHI sites of pEBG, a mammalian GST expression vector, to
generate pEBG–4-1BBCT. The plasmids, pEBG, pEBG-4-1BB,
and pEBG-CD30CT (28), were transfected into 293 cells. 48 h
after transfection, GST and GST fusion proteins were purified
with glutathione beads. For in vitro association experiments, the
full-length murine TRAF1 and TRAF2 cDNA in pBluescript
(Stratagene Inc., La Jolla, CA) were transcribed and translated in
vitro using the TNT coupled reticulocytes system (Promega)
with 
 
35
 
S-labeled methionine. Equal amounts of in vitro translated
TRAF1 or TRAF2 were incubated in binding buffer (PBS con-
taining 0.1% NP-40, 0.5 mM DTT, 10% glycerol, 1 mM PMSF,
and 2 
 
m
 
g/ml aprotinin) with 
 
z
 
5 
 
m
 
g of fusion protein bound to
glutathione beads for 45 min at 4
 
8
 
C. After washing five times
with binding buffer, the proteins were eluted by boiling in SDS
sample buffer for 5 min and subsequently analyzed by SDS-
PAGE.
 
Measurement of TRAF1 and TRAF2 Association with 4-1BB in
C8.A3 T Cells.
 
For measurement of TRAF1 and TRAF2 asso-
ciation in C8.A3 T hybrids, 2 
 
3 
 
10
 
7
 
 C8.A3 cells were incubated
on ice with 5 
 
m
 
g/ml of anti–4-1BB (1AH2) or with rat anti–
ICAM-1 (YN1) control antibody for 5 min. The antibody was
cross-linked with 20 
 
m
 
g/ml of RG7 (anti–rat 
 
k
 
 chain) for 15 min
at 37
 
8
 
C. After stimulation the cells were lysed with 10 mM Tris,
1 mM MgCl
 
2
 
, 50 mM NaCl, 0.5% NP-40, 2 
 
m
 
g/ml aprotinin,
and 1 mM PMSF. Lysates were immunoprecipitated for 4 h at
4
 
8
 
C with 40 
 
m
 
l of protein G–Sepharose (Sigma Chemical Co.).
For unstimulated controls, antibody and second step were added
on ice and the samples were carried through the same immuno-
precipitation protocol. Precipitated proteins were separated by
SDS-PAGE and transferred to nitrocellulose. TRAF proteins
were detected by polyclonal rabbit anti–murine TRAF1 (S-19)
and anti–murine TRAF2 (C-20) (Santa Cruz Biotechnologies,
Santa Cruz, CA). Bound antibodies were detected with goat
anti–rabbit Ig–horseradish peroxidase (Molecular Probes, Eugene,
OR) and detected by chemiluminescence according to the man-
ufacturer’s protocol (ECL system; Amersham Life Science, Ar-
lington Heights, IL).
 
T Cell Isolation.
 
APCs were depleted from spleen or lymph
node cell suspensions in HBSS (GIBCO BRL)/2.5% FCS/50
 
m
 
M 2-ME, with a cocktail of antibodies, anti–class II (Y3P), anti-
B220, anti–heat stable antigen (M1/69), anti–MAC-1, and anti-
CD11c (N418) each at a final concentration of 10 
 
m
 
g/ml at 4
 
8
 
C
for 30 min. A 1:10 dilution of baby rabbit complement (Cedar-
lane Labs. Ltd., Hornby, Ontario, Canada) was added, and the
cultures were further incubated at 37
 
8
 
C for 40 min. To remove
adherent cells, the cell suspensions were passaged through a
Sephadex G10/nylon wool column, and then centrifuged through
Percoll gradients consisting of 60, 70, and 80% Percoll layers.
Small (high density) T cells were isolated from the 70/80% inter-
face and used in all subsequent experiments. 
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T Cell Activation Assays.
 
Monoclonal anti-CD3 (145-2C11)
was immobilized on the surface of 96-well plates (Nunc, Gaith-
ersburg, MD) by incubating for 5 h at 37
 
8
 
C. Where indicated,
s4-1BBL or anti-CD28 antibodies were added to the wells at the
same time. 0.5–1 3 105 small high density T cells, from either
C57BL/6, CD282 mice, TRAF2 DN mice, TRAF22, or litter-
mate controls were cocultured with either immobilized anti-CD3
antibody alone, or in the presence of immobilized s4-1BBL, im-
mobilized anti-CD28, or control antibody as indicated in the fig-
ure legends. After 2 d the culture supernatants were collected,
and assayed for their ability to induce proliferation of the IL-2–
dependent cell line CTLLs as previously described (10).
Results
Generation of s4-1BBL Using the Baculovirus Expression
System. At the time we began these studies, Hurtado et al.
had shown that antibodies to 4-1BB could activate preacti-
vated T cells but were rather poor in the activation of rest-
ing T cells (12). In contrast, we had found that B lympho-
mas expressing 4-1BBL could induce high levels of IL-2
and IL-4 production by resting T cells (10, 16). Therefore,
it was possible either that 4-1BBL was more potent in acti-
vating resting T cells than were available antibodies or that
other molecules on the APC contributed to T cell activa-
tion by 4-1BBL. To distinguish these possibilities, we gen-
erated a soluble form of 4-1BBL using the baculovirus ex-
pression system.The entire extracellular domain of 4-1BBL
was expressed in isolation with the addition of an influenza
HA epitope tag at the COOH terminus of the protein to
facilitate purification (Fig. 1 A). Fig. 1 B shows a Coo-
massie blue–stained gel of purified s4-1BBL isolated from
the insect cells using 12CA5 (anti-HA) affinity chromatog-
raphy. It can be seen that s4-1BBL forms a disulfide-linked
dimer of z63 kD, consistent with the expected molecular
weight for the glycosylated form of the extracellular do-
main. The band is slightly heterogeneous, possibly due to
variable glycosylation or due to limited proteolysis.
Activation of CD281 and CD282 T Cells by 4-1BBL.
To assess the activity of s4-1BBL in the activation of resting
T cells, high density resting T cells from the spleens of
CD281 or CD282 mice were isolated by complement and
Sephadex G10 depletion of APCs followed by Percoll gra-
dient fractionation as described in Materials and Methods.
CD282 T cells were used to eliminate the possibility of any
contribution from CD28 signaling. Fig. 2 A shows IL-2
production by purified T cells responding to immobilized
anti-CD3 in the presence or absence of immobilized s4-
1BBL, added at 1 mg/ml. It can be seen that for both
CD281 and CD282 T cells, no IL-2 is generated in re-
sponse to immobilized anti-CD3 alone, but that coimmo-
bilization of s4-1BBL leads to significant IL-2 production.
s4-1BBL added in solution did not stimulate a response,
but s4-1BBL added in solution together with anti-HA anti-
body to cross-link the molecule via the HA tag was also ef-
fective in costimulation (data not shown). Fig. 2 B shows
the proliferation of CD282 T cells in response to immobi-
lized anti-CD3 alone or with 1 or 10 mg/ml immobilized
s4-1BBL. It can be seen that at suboptimal anti-CD3 con-
centrations, s4-1BBL enhances T cell proliferation. Fig. 2
C shows that the effect of s4-1BBL can be fully blocked by
coculture with a soluble form of the receptor, 4-1BB–AP,
whereas AP alone had no such effect. Thus, the enhance-
ment of IL-2 production in response to 4-1BBL is specific
to the soluble ligand.
Fig. 3 compares the sensitivity of CD281 and CD282 T
cells to s4-1BBL. It can be seen that the IL-2 response of
CD281 and CD282 T cells saturates at a concentration of
s4-1BBL of between 2 and 5 mg/ml. This titration experi-
ment was repeated using a different batch of purified s4-
1BBL and showed a similar saturation point (data not
shown). The response of CD282 T cells to s4-1BBL is
somewhat reduced compared with that of CD281 T cells.
Higher responses of CD281 versus CD282 T cells to s4-
1BBL might be due to low level expression of B7.2 on the
T cells or due to the presence of B7 on contaminating
APCs. Differences between the magnitude of the response
of CD281 and CD282 T cells to s4-1BBL were not appar-
ent in all experiments (for example, see Fig. 2) but tended
to vary with the particular T cell preparation. Similar dif-
ferences between CD281 and CD282 T cell responses to
4-1BBL were previously observed using 4-1BBL on APCs
(11). Flow cytometry analysis of CD281 and CD282 T
cells after overnight treatment with anti-CD3 showed sim-
ilar levels of induction of 4-1BB on the surface (data not
shown). Thus the difference in response to s4-1BBL on
CD281 or CD282 T cells does not appear to be due to dif-
ferential expression of 4-1BB in response to anti-CD3
treatment of CD281 or CD282 T cells.
Kinetics of IL-2 Production in Response to Anti-CD3 Plus
s4-1BBL. 4-1BB is an activation antigen on T cells. 4-1BB
Figure 1. Generation of a soluble form of 4-1BBL. (A) Schematic rep-
resentation of the construct used to generate s4-1BBL. MAG SS, MAG
signal sequence. (B) Coomassie blue–stained SDS-PAGE of s4-1BBL
produced in baculovirus and isolated from insect cell supernatants using
12CA5 anti-HA affinity chromatograpy as described in Materials and
Methods.1853 Saoulli et al.
mRNA appears within 3 h of anti-CD3 stimulation (45),
but surface expression of 4-1BB is not apparent until sev-
eral hours later (6). Therefore, it was important to establish
the kinetics of response to s4-1BBL. Fig. 4 shows IL-2 pro-
duction by resting CD282 T cells at various times after ex-
posure to immobilized anti-CD3 plus immobilized s4-
1BBL. It can be seen that IL-2 production by resting T
cells responding to anti-CD3 plus immobilized s4-1BBL is
detectable by 24 h with further increases in IL-2 produc-
tion by 48 h. The kinetics of response to s4-1BBL is similar
to the response of T cells to 4-1BBL expressed on B lym-
phomas, where we detected some IL-2 production by 12 h
with increasing amounts at 24–48 h (11). Thus the kinetics
of the response to s4-1BBL appears to be rapid enough to
explain the ability of 4-1BBL to activate resting T cells and
suggests that quite low levels of 4-1BB on the T cell surface
may be sufficient to provide T cell costimulation.
Comparison of Costimulatory Activity of 4-1BBL with Anti-
CD28 Antibodies. To compare the efficacy of the 4-1BB
versus CD28 costimulatory pathways for resting T cell acti-
vation, we compared T cell responses to immobilized anti-
CD28 and immobilized s4-1BBL in the presence of various
doses of anti-CD3 as shown in Fig. 5. Anti-CD28 was ti-
trated in a separate experiment (data not shown) and the
concentration which gives maximum stimulation when
immobilized with 1 mg/ml of anti-CD3 (10 mg/ml anti-
CD28) was compared with s4-1BBL at 5 mg/ml. It can be
seen that at low doses of anti-CD3, anti-CD28 is more ef-
fective than s4-1BBL in stimulating IL-2 production by
resting CD281 T cells. However, if one increases signals
through the TCR, via increasing the density of immobi-
lized anti-CD3, then 4-1BBL and anti-CD28 induce simi-
larly high levels of IL-2 production by resting CD281 T
cells. As expected, only s4-1BBL but not anti-CD28 en-
hanced IL-2 production by CD282 T cells. Thus, 4-1BBL
can provide a similar level of costimulation as anti-CD28
when provided with a strong TCR stimulus, but is less ef-
fective when signals through the TCR are limiting.
Association of 4-1BB with TRAF1 and TRAF2. The mech-
anism by which 4-1BB signals T cells to costimulate IL-2
Figure 2. Immobilized s4-1BBL can costimulate proliferation and IL-2 production by CD281 or CD282 T cells. (A) High density resting T cells iso-
lated from the spleens of CD281 or CD282 mice were incubated with various concentrations of anti-CD3 alone or with anti-CD3 plus immobilized s4-
1BBL added to the plastic wells at 1 mg/ml as indicated in the figures. After 48 h, culture supernatants were removed and serial dilutions of supernatant
were incubated with IL-2–dependent CTLL cells for 18–24 h. [3H]thymidine was added for the last 6 h of the CTLL culture. Data are shown for the first
dilution of culture supernatant and are representative of four independent experiments. (B) CD282 T cells were cultured with immobilized anti-CD3
alone or with immobilized anti-CD3 plus s4-1BBL at 1 or 10 mg/ml as indicated in the figure. After 48 h, [3H]thymidine was added to the wells and thy-
midine uptake was determined after a further 6 h of culture. Similar results were obtained in three separate experiments. (C) CD282 cells were cultured
with anti-CD3 (1 mg/ml) in the presence or absence of s4-1BBL (1 mg/ml) or in the presence of s4-1BBL (1 mg/ml) plus 4-1BB-AP (10 mg/ml). After
48-h incubation, culture supernatants were analyzed for induction of thymidine incorporation by CTLL. 4-1BB–AP alone had no effect on IL-2 produc-
tion. Results are shown for serial dilutions of the culture supernatants and are representative of four independent experiments.1854 CD28-independent, TRAF2-dependent T Cell Activation by 4-1BB Ligand
production is not known. 4-1BB is a member of the
TNFR family of signaling molecules. As discussed above,
the TRAF family of signaling molecules appear to function
as adapter proteins in the signal transduction cascades lead-
ing to NF-kB and JNK activation by members of this fam-
ily. Since TRAF2 has been shown to interact directly with
the cytoplasmic tails of several TNFR family molecules, we
chose to focus on a possible role for TRAF2 in 4-1BB sig-
naling. Therefore, the 4-1BB cytoplasmic domain was ex-
pressed as a GST fusion protein in 293 cells. Purified 4-1BB–
CT-GST bound to glutathione Sepharose was used to probe
the association of the 4-1BB cytoplasmic domain with in
vitro translated 35S-methionine labeled TRAF1 and TRAF2
proteins (Fig. 6). TRAF1 and TRAF2 were found to asso-
ciate with 4-1BB–CT-GST as well as CD30-GST (in-
cluded as a positive control). No association was observed
between TRAF1 and TRAF2 and GST alone.
We also attempted to detect TRAF association with the
4-1BB–CT-GST protein in 293 cells, but were not suc-
cessful (data not shown), which suggests that in cells, aggre-
gation of 4-1BB might be required to induce TRAF asso-
ciation as has been shown for CD40/TRAF association
(44). To test this hypothesis, we analyzed the association of
TRAF1 and TRAF2 with full-length 4-1BB in the T cell
hybridoma C8.A3. This T cell hybridoma has been shown
previously to respond to 4-1BB signaling and expresses low
levels of 4-1BB in the resting state, with further upregula-
tion of 4-1BB after overnight treatment with anti-CD3
(10). C8.A3 cells were incubated with anti–4-1BB and
goat anti–rat Ig for 15 min at 378C or on ice, after which
time the cells were lysed and protein G–Sepharose added to
immunoprecipitate the complex. When 4-1BB was cross-
linked at 08C little or no TRAF1 or TRAF2 could be de-
tected by Western blot analysis of the immunoprecipitated
material (Fig. 7). In contrast, aggregation of 4-1BB at 378C
using anti–4-1BB followed by anti–rat Ig induced the asso-
ciation of TRAF1 and TRAF2 with the 4-1BB precipi-
tates. Cross-linking of ICAM-1 on the T cells using rat
anti–ICAM-1 and anti–rat Ig at 378C did not result in sig-
nificant levels of TRAF1 or TRAF2 in the ICAM-1 im-
munoprecipitates (Fig. 7). Thus, the presence of TRAF1
and TRAF2 in the immunoprecipitates is specific to the
4-1BB molecule. These results show that cross-linking of
4-1BB on T cells results in its enhanced association with
TRAF1 and TRAF2 and that there is little or no TRAF1
and TRAF2 associated with 4-1BB in the resting state.
Role of the TRAF Family of Signaling Molecules in Costimu-
lation of IL-2 Production by s4-1BBL. Based on the associ-
ation of the 4-1BB cytoplasmic domain with TRAF2 (Figs.
6 and 7) and the importance of TRAF2 in JNK activation
in response to TNF, we explored the functional role of
TRAF2 using T cells isolated from TRAF22 mice, as well
as using T cells isolated from TRAF2 DN mice.
To test the effect of the TRAF2 DN mutant on 4-1BB
Figure 3. Effect of 4-1BBL ti-
tration on CD281 and CD282 T
cell responses. High density rest-
ing T cells isolated from the
spleens of CD281 or CD282
mice were incubated with anti-
CD3 alone (1 mg/ml) or with
anti-CD3 plus immobilized s4-
1BBL added to the plastic wells
at the concentration indicated in
the figures. After 2 d, serial di-
lutions of the culture supernatant
were incubated with IL-2–
dependent  CTLL cells overnight.
[3H]thymidine was added to the
CTLL cultures for the last 6 h of
culture. Similar results were ob-
tained in three independent ex-
periments.1855 Saoulli et al.
signaling leading to IL-2 production, we isolated high den-
sity resting T cells from TRAF2 DN mice and their trans-
gene negative littermates. Fig. 8 compares IL-2 production
by the T cells in response to anti-CD3 alone, anti-CD3
plus immobilized s4-1BBL or anti-CD3 plus immobilized
anti-CD28 antibody. For the wild-type T cells, immobi-
lized s4-1BBL clearly augments the response of resting
spleen or lymph node T cells to immobilized anti-CD3. As
was observed in Fig. 5, the effects of s4-1BBL on IL-2 pro-
duction are smaller than those of anti-CD28. The TRAF2
DN T cells showed a higher background response to anti-
CD3 alone and addition of s4-1BBL actually led to a de-
crease in response of the TRAF2 DN T cells. In contrast,
anti-CD28 augmented IL-2 production in response to anti-
CD3 in both the wild-type mice and TRAF2 DN mice.
Although responses to anti-CD28 were retained in all in-
stances, with lymph node T cells we sometimes observed a
lower response to anti-CD28 in transgenic T cells com-
pared with the nontransgenic controls (e.g., anti-CD28 at
10 mg/ml in Fig. 8). In contrast, splenic T cells sometimes
showed hyperresponsiveness to anti-CD28 (e.g., anti-
CD28 2 mg/ml, Fig. 8). In spite of the variable response to
anti-CD28, the observation that the TRAF2 DN mice
largely retain responses to anti-CD28 but fail to show aug-
mentation of IL-2 production in response to immobilized
s4-1BBL suggests that the TRAF2 signaling molecule is re-
quired for 4-1BB signaling.
Fig. 9 shows a similar experiment carried out using T
cells isolated from the lymph nodes of TRAF22 mice. As
Figure 4. Kinetics of IL-2 production in response to 4-1BBL. Resting
T cells isolated from the spleens of CD282 mice were incubated with
anti-CD3 alone (1 mg/ml) or with anti-CD3 plus s4-1BBL immobilized
at the concentrations indicated on the figure. After 12, 24, or 48 h, cul-
ture supernatants were removed and serial dilutions were analyzed for in-
duction of proliferation of IL-2–dependent CTLL cells. Results are repre-
sentative of two separate experiments.
Figure 5. Comparison of immobilized s4-1BBL with immobilized
anti-CD28 for costimulation of IL-2 production by CD281 and CD282 T
cells. Resting T cells isolated from CD281 or CD282 T cells were stimu-
lated by immobilized anti-CD3 at the indicated concentrations plus or
minus 4-1BBL immobilized at 5 mg/ml or anti-CD28 at 10 mg/ml or
control Ig at 10 mg/ml. After 48 h, supernatants were removed and ana-
lyzed for the presence of IL-2 using CTLL cells. Results are representative
of two independent experiments.1856 CD28-independent, TRAF2-dependent T Cell Activation by 4-1BB Ligand
described elsewhere, TRAF22 mice have small lymphoid
organs and die on average at day 10–14 after birth (36).
However, some mice survived to 3 wk and were used for
these experiments. The spleens of these mice are atrophied
and could not be used for T cell isolation, but a small num-
ber of resting T cells could be isolated from the lymph
nodes of these animals. It can be seen that the T cells from
the TRAF22 mice retain the ability to respond to anti-
CD28, but show no enhancement of anti-CD3 signaling
by immobilized 4-1BBL. Again, the response to anti-CD3
alone was higher in the TRAF2-deficient animals than the
littermate controls and the addition of 4-1BBL actually re-
duces the response to anti-CD3 alone. Similarly to the re-
sults with lymph node T cells from the TRAF2 DN mice
(Fig. 8), the response of lymph node T cells to anti-CD3
plus anti-CD28 was also somewhat reduced.
In addition to TRAF2, the 4-1BB cytoplasmic domain
also interacts with TRAF1 (Figs. 6 and 7). T cells from
transgenic mice that overexpress TRAF1 have been shown
to proliferate normally in response to TCR engagement,
but are resistant to antigen-induced apoptosis (38). Consis-
tent with the observations that TRAF1 overexpression
does not influence T cell proliferative responses (38), we
find that T cells from mice overexpressing TRAF1 showed
no differences in IL-2 production in response to anti-CD3
plus immobilized s4-1BBL compared with wild-type con-
trols (data not shown).
Discussion
The delivery of a signal through the CD28 molecule has
been shown to be critical for activation of T cells and for
prevention of induction of cell death or an anergic state.
For a costimulatory receptor to prevent the induction of
anergy, it is thought that the costimulatory signal must be
delivered simultaneously or within a few hours of signaling
through the TCR (46). Previous studies using antibodies to
4-1BB to stimulate T cells have found that unprimed T
cells require 4–5 d to respond to anti–4-1BB, but that T
cells that have been preactivated for 2–3 d to induce a high
level 4-1BB expression, respond within 48 h (6, 12). Our
Figure 6. Association between the 4-1BB cytoplasmic tail-GST fusion
protein and TRAF1 and TRAF2 proteins. As described in Materials and
Methods, purified GST, GST-CD30CT, and GST–4-1BBCT proteins
bound to glutathione beads were incubated with 35S-labeled in vitro–
translated TRAF1 or TRAF2. After washing, samples were eluted and
analyzed by SDS-PAGE followed by autoradiography. In vitro–translated
TRAF1 and TRAF2 were also run directly on the gel (lanes marked
TRAF1 and TRAF2) for comparison.
Figure 7. Association of
TRAF1 and TRAF2 with 4-1BB
in a T cell hybrid is induced by
receptor aggregation at 378C.
C8.A3 T cells (2 3 107 cells/
lane) were stimulated with anti–
4-1BB or with anti–ICAM-1 on
ice for 5 min and then cross-
linked with anti–rat Ig for 15
min on ice or at 378C. Lysates
were immunoprecipitated with
protein G–Sepharose. Immuno-
precipitates were separated by
SDS-PAGE and analyzed by
Western blotting with either
anti-TRAF1 or anti-TRAF2.
This experiment is representative
of three separate experiments.1857 Saoulli et al.
Figure 8. Decreased response to 4-1BBL by T cells isolated from mice expressing a dominant negative form of TRAF2. Resting T cells were isolated
from spleen and lymph nodes TRAF2 DN mice or their transgene-negative littermates, as described in Materials and Methods. T cells were incubated
with anti-CD3 immobilized on plastic at the concentrations indicated in the figures in the presence or absence of immobilized s4-1BBL (5 mg/ml) or im-
mobilized anti-CD28 at 2 or 10 mg/ml as indicated in the figure. At 48 h of culture, supernatants were analyzed for IL-2 production using CTLL cells. Re-
sults shown are for a single representative mouse. Similar results were obtained in three independent experiments with two control and two mutant mice
analyzed separately in each experiment.1858 CD28-independent, TRAF2-dependent T Cell Activation by 4-1BB Ligand
data using 4-1BBL on APCs (11) or using s4-1BBL (this
report) show that T cells can produce IL-2 in response to
4-1BBL within 24 h in the absence of CD28 costimula-
tion. Other studies in which antibodies to 4-1BB have
been used to costimulate with anti-CD3 either used preac-
tivated T cells (12) or did not separate resting from acti-
vated T cells (14). Because B7 family members are ex-
pressed on activated T cells, one cannot rule out that low
levels of B7 were also contributing to the response in these
studies (12, 14). Although we have previously shown that
CD282 T cells can respond to 4-1BBL expressed on APCs
(16), in those studies it was possible that other molecules
present on the cell surface contributed to this signal. Our
study therefore used purified resting T cells from CD282
mice and soluble 4-1BBL to test the role of 4-1BBL in iso-
lation. The data presented here clearly show that 4-1BBL
alone can provide an effective costimulatory signal for rest-
ing T cell activation, independent of other cell surface mol-
ecules including the CD28 molecule.
The ability of s4-1BBL to induce IL-2 in T cells more
rapidly than anti–4-1BB antibody may be due to the natu-
ral ligand for 4-1BB providing a more potent signal than
that delivered by antibody ligation. Although surface ex-
pression of 4-1BB is not obvious until at least 24 h after
anti-CD3 treatment of resting T cells (6), 4-1BB mRNA is
readily detectable within 3 h of anti-CD3 treatment (45).
Our data showing that functional responses to isolated
4-1BBL occur within 24 h of T cell activation suggests that
it may take only a few 4-1BB molecules on the T cell sur-
face to allow costimulatory signals to be transduced. Thus,
our data show that 4-1BBL can, under appropriate condi-
tions, function in a similar way to and independently of the
CD28 molecule to provide a costimulatory signal for in-
duction of IL-2 production by resting T cells.
A comparison of the costimulatory activity of immobi-
lized anti-CD28 and immobilized s4-1BBL (Fig. 5) showed
that anti-CD28 is more effective than immobilized s4-
1BBL in inducing IL-2 production at low doses of anti-
CD3. However, at higher concentrations of anti-CD3, one
can achieve similar levels of IL-2 production in response to
CD28 or 4-1BB engagement. CD28 is expressed on resting
T cells, whereas 4-1BB is expressed only after signaling
through the TCR. When anti-CD3 is bound to the plates
at low density, the level of 4-1BB receptor induced may be
limiting, thus explaining the poorer response to s4-1BBL at
low anti-CD3 concentrations. Alternatively or additionally,
the lower response to s4-1BBL at low anti-CD3 doses
might be due to 4-1BBL providing a weaker costimulatory
signal than anti-CD28. This weaker signal from 4-1BBL–
4-1BB interaction may be compensated for by increasing
signals through the TCR. Nevertheless, when signals
through the TCR are optimized, 4-1BBL can function as
well as anti-CD28 in induction of IL-2 production by rest-
ing T cells (Fig. 5).
Figure 9. Decreased response
to 4-1BBL by T cells isolated
from TRAF22 mice. Resting T
cells were isolated from the
lymph nodes of TRAF22 mice
or their wild-type TRAF21 lit-
termates. T cells were incubated
with anti-CD3 alone (immobi-
lized at 1 mg/ml) or with anti-
CD3 plus immobilized s4-1BBL
(5 mg/ml) or immobilized anti-
CD28 (2 mg/ml). Results are
shown from one mouse and are
representative of two indepen-
dent experiments with two mice
per experiment.1859 Saoulli et al.
Shahinian et al. have shown that CD282 T cells are un-
impaired in their immune response to LCMV infection (2).
Interestingly, there is evidence that it is the duration of
TCR signaling that allows CD28-independent immune re-
sponses to LCMV (47). In light of our data, one could in-
terpret the data of Kündig et al. (47) as suggesting that anti-
gens that induce strong signals through the TCR may
allow other CD28-independent costimulatory pathways,
such as the 4-1BB pathway, to take over. The kinetics of
the response to s4-1BBL (Fig. 4) suggest that if signal 1 is
strong enough, then 4-1BB can be induced and receive
sufficient signals to induce IL-2 production within 24 h.
A critical question is how the various cell surface mole-
cules involved in T cell activation integrate the signals from
distinct signal transduction pathways to induce high level
IL-2 gene expression. T cell receptor signaling and CD28
signaling have been shown to synergize at the level of JNK
(48). TRAF2 has been implicated in the ability of both
TNFR1 and CD40 to activate JNK (32–36). Therefore, an
attractive hypothesis is that 4-1BB signaling can replace
CD28 signaling by synergizing with the TCR at the level
of JNK activation. As a first step toward testing this model,
we have analyzed the role of TRAF2 in T cell activation
by 4-1BB.
Using a GST fusion protein, we showed that the cyto-
plasmic domain of 4-1BB could associate with TRAF1 and
TRAF2 in vitro (Fig. 6). However, attempts to demon-
strate an association between the 4-1BB CT and TRAF1
and 2 in 293 cells using the same GST fusion protein were
not successful. This suggested that aggregation of 4-1BB
might be required for TRAF association in cells. In support
of this, we found that TRAF1 and TRAF2 association
with 4-1BB in a T cell hybrid required cross-linking of
4-1BB at 378C. During the revision of this manuscript, two
groups have also reported an association of TRAF1 and
TRAF2 with the 4-1BB cytoplasmic domain using yeast 2
hybrid analysis (49, 50). Arch and Thompson (49) demon-
strated TRAF1 and TRAF2 association with the murine
4-1BB cytoplasmic domain. In addition, using a fusion protein
between the murine 4-1BB cytoplasmic domain and the
transmembrane/extracellular domains of CD28, Arch and
Thompson found constitutive association of 4-1BB with
TRAF 2 in HEK293 cells (49). Jang et al. have reported that
TRAF1 and TRAF2 associate with human 4-1BB and they
find that when full-length 4-1BB and the TRAF proteins
are overexpressed in 293 these associations are observed in
the absence of 4-1BB receptor cross-linking (50). The dif-
ference between those studies and our results may reflect
the higher level of proteins expressed in the 293 cells versus
our use of endogenously expressed molecules in T cells.
In this report we have also shown that resting T cells iso-
lated from mice that lack TRAF2 or express a dominant
negative form of TRAF2 in their lymphoid subset fail to
respond to 4-1BB signaling. TRAF22 mice have very small
lymphoid organs and die at 2–3 wk of age, whereas mice
expressing a TRAF2 DN transgene in their lymphoid cells
are viable and have enlarged lymphoid organs due to the
presence of an abnormal number of B cells. In spite of these
marked phenotypic differences, both types of TRAF2-defi-
cient mice have demonstrated an essential role for TRAF2
in JNK activation in response to TNF (35, 36). Similarly,
in this report we have demonstrated that the two different
types of TRAF-deficient mice have very similar outcomes
for the T cell response to 4-1BBL. That is, responses to
anti-CD28 were retained, whereas responses to 4-1BBL
actually went from being stimulatory in wild-type mice, to
being inhibitory to anti-CD3–induced IL-2 production in
TRAF2-deficient mice (Figs. 8 and 9). The observation
that signaling via 4-1BB is actually slightly inhibitory to
anti-CD3–stimulated T cells is unexplained. It is possible
that this result is due to an inhibitory signal from 4-1BB
that is normally masked by the positive signaling effects of
TRAF2.
For both TRAF2 DN mice and TRAF22 mice, we also
observed an increase in background response to anti-CD3
alone. The reason for this increase in background is not
clear. The purity of T cells from TRAF2 DN mice or their
transgene-negative littermates was indistinguishable and ad-
dition of CTLA-4 Ig to block effects of B7 family mole-
cules had no effect on the response (data not shown). Thus,
the increased response of isolated resting T cells to immo-
bilized anti-CD3 does not appear to be due to the presence
of contaminating B7-expressing APCs. Lee et al. have
shown that the response of TRAF2 DN lymph node T
cells to anti-CD3 presented by accessory cells is decreased
compared with transgene-negative littermates (35). The
data in our report, showing a slight decrease in the response
of lymph node TRAF2 DN T cells to anti-CD3 and anti-
CD28, agrees with that finding. However, the increased
response to anti-CD3 alone (Figs. 8 and 9) is puzzling. Yeh
et al. have shown that serum levels of TNF are increased in
TRAF2-deficient animals and have suggested that lack of
TRAF2 leads to dysregulation of TNF synthesis (36). It is
possible that the dysregulation of TRAF2 prevents feed-
back inhibition of the expression of other molecules pro-
duced by or expressed on the purified T cells, and that
these in turn allow enhancement of the response to anti-
CD3 alone.
In addition to associating with TRAF2 (Figs. 6 and 7),
the 4-1BB cytoplasmic tail can also associate with TRAF1
in vitro. The biological significance of this finding remains
to be tested. In contrast to the results with TRAF2-nega-
tive mice or with mice expressing a dominant negative
form of TRAF2, T cells from mice that overexpress wild-
type TRAF1 showed no perturbation of responses to anti-
CD3 plus anti-CD28 or s4-1BBL (data not shown). These
results are not surprising in view of the data from Speiser
et al., which showed that T cells from the TRAF1 overex-
pressing mice have normal proliferative responses but are
resistant to antigen-induced apoptosis (38). This lack of
perturbation of 4-1BB signaling by overexpression of
TRAF1 could be due to the dispensability of TRAF1 for
4-1BB costimulatory signals or could be because the
amount of TRAF1 recruited during 4-1BB signaling in
wild-type mice is not limiting. It was also possible that
overexpression of TRAF1 would interfere with signaling1860 CD28-independent, TRAF2-dependent T Cell Activation by 4-1BB Ligand
via TRAF2 by forming heterodimers that prevent other in-
teractions of the TRAF2 molecule, but this did not seem to
occur, as 4-1BB signaling was neither impaired nor en-
hanced by overexpression of TRAF1 (data not shown).
In summary, the results presented here show that 4-1BBL
can function in isolation to costimulate T cell responses
that are independent of the CD28 molecule. When signal-
ing through the TCR is strong, 4-1BB signaling is as effec-
tive as anti-CD28 signaling in stimulating IL-2 production
by T cells. In contrast, at low anti-CD3 doses, the CD28
costimulatory pathway seems to be more effective than the
4-1BB costimulatory pathway. The induction of IL-2 in
response to the 4-1BB costimulatory signal is dependent on
the presence of a functional TRAF2 molecule. Given the
importance of TRAF2 in JNK activation in response to
CD40L or TNF, a plausible model is that synergistic acti-
vation of JNK by TCR plus 4-1BB via TRAF2 leads to
high level IL-2 gene transcription and in this way the 4-1BB
molecule can replace the CD28 molecule in resting T cell
activation. Thus, our data add to the accumulating body of
evidence for a pivotal role for the TRAF2 molecule in sig-
naling by TNFR family members.
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